ERYTECH Pharma S.A. (ERYP) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Lyon, France. The current CEO is Gil Beyen.
ERYP has IPO date of 2016-07-05, 49 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $47.38M.
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
